Hmdb loader
Survey
You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on Human Metabolome Database.
Record Information
Version5.0
StatusExpected but not Quantified
Creation Date2012-09-06 15:16:52 UTC
Update Date2022-03-07 02:51:59 UTC
HMDB IDHMDB0015434
Secondary Accession Numbers
  • HMDB15434
Metabolite Identification
Common NameForasartan
DescriptionForasartan, also known as SC 52458, belongs to the class of organic compounds known as phenylpyridines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyridine ring through a CC or CN bond. Forasartan is a drug which is used for the treatment of hypertension. Forasartan is a strong basic compound (based on its pKa). Forasartan is a competitive and reversible ARB that competes with the angiotensin II binding site on AT1 and relaxes vascular smooth muscle, resulting in decreased blood pressure. Research demonstrates that forasartan is also significantly less potent than losartan. In humans, forasartan is involved in forasartan action pathway. Forasartan administration selectively inhibits L-type calcium channels in the plateau component of the smooth muscle cells, favoring relaxation of the smooth muscle. Forasartan also decreases heart rate by inhibiting the positive chronotropic effect of high frequency preganglionic stimuli. Forasartan is indicated for the treatment of hypertension and, similar to other ARBs, it protects the kidneys from kidney blood vessel damage caused by increased kidney blood pressure by blocking renin–angiotensin system activation. Smooth muscle contraction occurs due to increased calcium influx through the L-type calcium channels in smooth muscle cells during the plateau component, increasing the intracellular calcium and membrane potential which sustain depolarization and contraction. The dose administered ranges between 150 mg-200 mg daily.
Structure
Data?1582753297
Synonyms
ValueSource
ForasartanumChEBI
SC 52458ChEBI
SC-52458ChEBI
5-((3,5-Dibutyl-1H-1,2,4-triazol-1-yl)methyl)-2-(2-(1H-tetrazol-5-ylphenyl))pyridineHMDB
Fora-sartanHMDB
Chemical FormulaC23H28N8
Average Molecular Weight416.522
Monoisotopic Molecular Weight416.243692936
IUPAC Name5-[(dibutyl-1H-1,2,4-triazol-1-yl)methyl]-2-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]pyridine
Traditional Nameforasartan
CAS Registry Number145216-43-9
SMILES
CCCCC1=NN(CC2=CN=C(C=C2)C2=CC=CC=C2C2=NNN=N2)C(CCCC)=N1
InChI Identifier
InChI=1S/C23H28N8/c1-3-5-11-21-25-22(12-6-4-2)31(28-21)16-17-13-14-20(24-15-17)18-9-7-8-10-19(18)23-26-29-30-27-23/h7-10,13-15H,3-6,11-12,16H2,1-2H3,(H,26,27,29,30)
InChI KeyYONOBYIBNBCDSJ-UHFFFAOYSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as phenylpyridines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyridine ring through a CC or CN bond.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassPhenylpyridines
Direct ParentPhenylpyridines
Alternative Parents
Substituents
  • 2-phenylpyridine
  • Phenyltetrazole
  • Benzenoid
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • 1,2,4-triazole
  • Tetrazole
  • Azole
  • Azacycle
  • Organic nitrogen compound
  • Organopnictogen compound
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Ontology
Physiological effectNot Available
Disposition
Process
RoleNot Available
Physical Properties
StateSolid
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water Solubility0.0067 g/LNot Available
LogPNot AvailableNot Available
Experimental Chromatographic PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
Water Solubility0.0067 g/LALOGPS
logP4.51ALOGPS
logP5.89ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)7.35ChemAxon
pKa (Strongest Basic)3.99ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area98.06 ŲChemAxon
Rotatable Bond Count10ChemAxon
Refractivity145.44 m³·mol⁻¹ChemAxon
Polarizability46.79 ųChemAxon
Number of Rings4ChemAxon
BioavailabilityYesChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DarkChem[M+H]+197.98831661259
DarkChem[M-H]-201.11431661259
DeepCCS[M+H]+198.60330932474
DeepCCS[M-H]-196.24530932474
DeepCCS[M-2H]-230.42130932474
DeepCCS[M+Na]+205.6530932474
AllCCS[M+H]+204.532859911
AllCCS[M+H-H2O]+202.232859911
AllCCS[M+NH4]+206.732859911
AllCCS[M+Na]+207.332859911
AllCCS[M-H]-199.832859911
AllCCS[M+Na-2H]-200.532859911
AllCCS[M+HCOO]-201.532859911

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
ForasartanCCCCC1=NN(CC2=CN=C(C=C2)C2=CC=CC=C2C2=NNN=N2)C(CCCC)=N14332.1Standard polar33892256
ForasartanCCCCC1=NN(CC2=CN=C(C=C2)C2=CC=CC=C2C2=NNN=N2)C(CCCC)=N13683.9Standard non polar33892256
ForasartanCCCCC1=NN(CC2=CN=C(C=C2)C2=CC=CC=C2C2=NNN=N2)C(CCCC)=N13742.7Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Forasartan,1TMS,isomer #1CCCCC1=NN(CC2=CC=C(C3=CC=CC=C3C3=NN([Si](C)(C)C)N=N3)N=C2)C(CCCC)=N13901.5Semi standard non polar33892256
Forasartan,1TMS,isomer #1CCCCC1=NN(CC2=CC=C(C3=CC=CC=C3C3=NN([Si](C)(C)C)N=N3)N=C2)C(CCCC)=N13822.3Standard non polar33892256
Forasartan,1TMS,isomer #1CCCCC1=NN(CC2=CC=C(C3=CC=CC=C3C3=NN([Si](C)(C)C)N=N3)N=C2)C(CCCC)=N14962.5Standard polar33892256
Forasartan,1TBDMS,isomer #1CCCCC1=NN(CC2=CC=C(C3=CC=CC=C3C3=NN([Si](C)(C)C(C)(C)C)N=N3)N=C2)C(CCCC)=N14003.4Semi standard non polar33892256
Forasartan,1TBDMS,isomer #1CCCCC1=NN(CC2=CC=C(C3=CC=CC=C3C3=NN([Si](C)(C)C(C)(C)C)N=N3)N=C2)C(CCCC)=N14025.6Standard non polar33892256
Forasartan,1TBDMS,isomer #1CCCCC1=NN(CC2=CC=C(C3=CC=CC=C3C3=NN([Si](C)(C)C(C)(C)C)N=N3)N=C2)C(CCCC)=N14893.0Standard polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - Forasartan GC-MS (Non-derivatized) - 70eV, Positivesplash10-00dr-2119100000-e04b6124d350613840ca2017-09-01Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Forasartan GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Forasartan 10V, Positive-QTOFsplash10-014i-0011900000-82f2b8054d8a70abdd4b2016-08-02Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Forasartan 20V, Positive-QTOFsplash10-00kr-0239300000-c761990a428a03b7d0312016-08-02Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Forasartan 40V, Positive-QTOFsplash10-0a4r-3492000000-1caaf1e75870b4c29d8a2016-08-02Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Forasartan 10V, Negative-QTOFsplash10-00lr-0900500000-3aed9e02ff522163c56e2016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Forasartan 20V, Negative-QTOFsplash10-00lr-0932400000-34fac54d64efb89db0922016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Forasartan 40V, Negative-QTOFsplash10-001i-9610000000-e6e63055f5e11a58ec4a2016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Forasartan 10V, Positive-QTOFsplash10-014i-0000900000-e582bd677f5dc3d1574c2021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Forasartan 20V, Positive-QTOFsplash10-014i-0014900000-15e9aca84c5d255c5adf2021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Forasartan 40V, Positive-QTOFsplash10-052r-2493000000-2306fba8af7044bc78382021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Forasartan 10V, Negative-QTOFsplash10-014i-0000900000-d5987697aba0ae95495c2021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Forasartan 20V, Negative-QTOFsplash10-014i-0029800000-6bb80664ce7eeee384d32021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Forasartan 40V, Negative-QTOFsplash10-00xr-2964000000-2e9a6c661f210ddd83432021-10-11Wishart LabView Spectrum
Biological Properties
Cellular Locations
  • Membrane
Biospecimen Locations
  • Blood
  • Urine
Tissue LocationsNot Available
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB01342 details
UrineExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB01342 details
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDDB01342
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider ID117146
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkForasartan
METLIN IDNot Available
PubChem Compound132706
PDB IDNot Available
ChEBI ID141552
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General ReferencesNot Available

Enzymes

General function:
Involved in G-protein coupled receptor protein signaling pathway
Specific function:
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol- calcium second messenger system
Gene Name:
AGTR1
Uniprot ID:
P30556
Molecular weight:
41060.5
References
  1. Tokunaga R, Kushiku K, Yamada K, Yamada H, Furukawa T: Possible involvement of calcium-calmodulin pathways in the positive chronotropic response to angiotensin II on the canine cardiac sympathetic ganglia. Jpn J Pharmacol. 2001 Aug;86(4):381-9. [PubMed:11569611 ]
  2. Usune S, Furukawa T: Effects of SC-52458, a new nonpeptide angiotensin II receptor antagonist, on increase in cytoplasmic Ca2+ concentrations and contraction induced by angiotensin II and K(+)-depolarization in guinea-pig taenia coli. Gen Pharmacol. 1996 Oct;27(7):1179-85. [PubMed:8981065 ]
  3. Hagmann M, Nussberger J, Naudin RB, Burns TS, Karim A, Waeber B, Brunner HR: SC-52458, an orally active angiotensin II-receptor antagonist: inhibition of blood pressure response to angiotensin II challenges and pharmacokinetics in normal volunteers. J Cardiovasc Pharmacol. 1997 Apr;29(4):444-50. [PubMed:9156352 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]